N Engl J Med 2014 Sep 27
Crizotinib in ROS1-Rearranged Non-Small-Cell Lung Cancer.   

Related Questions

Should mutations other then EGFR and ALK be routinely tested for? Should next generation sequencing be routinely done?

If starting with entrectinib would you still try crizotinib, or move to lorlatinib or another novel TKI? Or change entirely to chemotherapy, immunothe...